

Nesri Padayatchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8399072/publications.pdf>

Version: 2024-02-01

117
papers

6,491
citations

109137

35
h-index

69108

77
g-index

121
all docs

121
docs citations

121
times ranked

6294
citing authors

#	ARTICLE	IF	CITATIONS
1	Tuberculosis Elimination in the Era of Coronavirus Disease 2019 (COVID-19): A Moving Target. <i>Clinical Infectious Diseases</i> , 2022, 74, 509-510.	2.9	10
2	Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps. <i>Lancet HIV</i> , 2022, 9, e130-e138.	2.1	7
3	Mortality in HIV and tuberculosis patients following implementation of integrated HIV-TB treatment: Results from an open-label cluster-randomized trial. <i>EClinicalMedicine</i> , 2022, 44, 101298.	3.2	4
4	Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field. <i>Frontiers in Microbiology</i> , 2022, 13, 775030.	1.5	22
5	Electronic Dose Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis and Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e1901-e1910.	2.9	12
6	Plasma Biomarkers of Risk of Tuberculosis Recurrence in HIV Co-Infected Patients From South Africa. <i>Frontiers in Immunology</i> , 2021, 12, 631094.	2.2	7
7	The effect of human immunodeficiency virus infection on adverse events during treatment of drug-resistant tuberculosis: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0248017.	1.1	8
8	Dynamic needs and challenges of people with drug-resistant tuberculosis and HIV in South Africa: a qualitative study. <i>The Lancet Global Health</i> , 2021, 9, e479-e488.	2.9	25
9	Effect of Inflammatory Cytokines/Chemokines on Pulmonary Tuberculosis Culture Conversion and Disease Severity in HIV-Infected and -Uninfected Individuals From South Africa. <i>Frontiers in Immunology</i> , 2021, 12, 641065.	2.2	11
10	Acceptability, feasibility, and impact of a pilot tuberculosis literacy and treatment counselling intervention: a mixed methods study. <i>BMC Infectious Diseases</i> , 2021, 21, 449.	1.3	3
11	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. <i>The Lancet Global Health</i> , 2021, 9, e841-e853.	2.9	34
12	A Quality Improvement Intervention to Inform Scale-Up of Integrated HIV-TB Services: Lessons Learned From KwaZulu-Natal, South Africa. <i>Global Health, Science and Practice</i> , 2021, 9, 444-458.	0.6	2
13	Organizational contextual factors that predict success of a quality improvement collaborative approach to enhance integrated HIV-tuberculosis services: a sub-study of the Scaling up TB/HIV Integration trial. <i>Implementation Science</i> , 2021, 16, 88.	2.5	1
14	A cluster-randomized controlled trial to improve the quality of integrated HIV-tuberculosis services in primary healthcare clinics in South Africa. <i>Journal of the International AIDS Society</i> , 2021, 24, e25803.	1.2	5
15	A Moxifloxacin-based Regimen for the Treatment of Recurrent, Drug-sensitive Pulmonary Tuberculosis: An Open-label, Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2020, 70, 90-98.	2.9	12
16	High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB Trial. <i>Clinical Infectious Diseases</i> , 2020, 70, 2675-2682.	2.9	13
17	High incidence and persistence of hepatitis B virus infection in individuals receiving HIV care in KwaZulu-Natal, South Africa. <i>BMC Infectious Diseases</i> , 2020, 20, 847.	1.3	13
18	Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. <i>Lancet Microbe</i> , 2020, 1, e165-e174.	3.4	71

#	ARTICLE	IF	CITATIONS
19	Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1/TB-co-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3319-3326.	1.3	9
20	Dynamics of within-host <i>Mycobacterium tuberculosis</i> diversity and heteroresistance during treatment. <i>EBioMedicine</i> , 2020, 55, 102747.	2.7	52
21	Individualized Treatment of Multidrug-resistant Tuberculosis Using Whole-Genome Sequencing and Expanded Drug-Susceptibility Testing. <i>Clinical Infectious Diseases</i> , 2020, 71, 2981-2985.	2.9	3
22	Neurocognitive functioning in MDR-TB patients with and without HIV in KwaZulu-Natal, South Africa. <i>Tropical Medicine and International Health</i> , 2020, 25, 919-927.	1.0	4
23	Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. <i>European Respiratory Journal</i> , 2020, 55, 1902383.	3.1	60
24	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. <i>Scientific Reports</i> , 2020, 10, 8629.	1.6	90
25	Mapping the tuberculosis scientific landscape among BRICS countries: a bibliometric and network analysis. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2020, 115, e190342.	0.8	15
26	Major Depression and Stigma among Individuals with Multidrug-Resistant Tuberculosis in South Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1067-1071.	0.6	10
27	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 820-826.	5.2	92
28	Quality of TB care among people living with HIV: Gaps and solutions. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2019, 17, 100122.	0.6	10
29	Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. <i>Frontiers in Microbiology</i> , 2019, 10, 1441.	1.5	46
30	Precision medicine in resistant Tuberculosis: Treat the correct patient, at the correct time, with the correct drug. <i>Journal of Infection</i> , 2019, 78, 261-268.	1.7	13
31	Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. <i>Lancet HIV</i> , 2019, 6, e201-e204.	2.1	24
32	Major depression and household food insecurity among individuals with multidrug-resistant tuberculosis (MDR-TB) in South Africa. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2019, 54, 387-393.	1.6	24
33	Tuberculosis: treatment failure, or failure to treat? Lessons from India and South Africa. <i>BMJ Global Health</i> , 2019, 4, e001097.	2.0	34
34	Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. <i>Pharmacogenomics</i> , 2019, 20, 225-240.	0.6	32
35	Neurocognitive Impairment Risk Among Individuals With Multiple Drug-Resistant Tuberculosis and Human Immunodeficiency Virus Coinfection. <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 307-310.	0.5	6
36	Transmission of drug-resistant tuberculosis in HIV-endemic settings. <i>Lancet Infectious Diseases</i> , 2019, 19, e77-e88.	4.6	47

#	ARTICLE	IF	CITATIONS
37	Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review. <i>European Respiratory Journal</i> , 2019, 53, 1801030.	3.1	38
38	Rural medicine and "home stay": a medical student's experience. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2018, 60, 216-218.	0.2	1
39	Evolution of drug resistance in <i>Mycobacterium tuberculosis</i> : a review on the molecular determinants of resistance and implications for personalized care. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1138-1151.	1.3	219
40	Effect of genetic variation in <i>UGT1A</i> and <i>ABCB1</i> on moxifloxacin pharmacokinetics in South African patients with tuberculosis. <i>Pharmacogenomics</i> , 2018, 19, 17-29.	0.6	16
41	TB epidemiology: where are the young women? Know your tuberculosis epidemic, know your response. <i>BMC Public Health</i> , 2018, 18, 417.	1.2	12
42	Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa. <i>BMC Infectious Diseases</i> , 2018, 18, 171.	1.3	37
43	Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 536-542.	0.9	7
44	Effect of Antiretroviral Therapy on Treatment Outcomes in a Prospective Study of Extensively Drug-Resistant Tuberculosis (XDR-TB) HIV Coinfection Treatment in KwaZulu-Natal, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 474-480.	0.9	14
45	Recurrent tuberculosis among HIV-coinfected patients: a case series from KwaZulu-Natal. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1413-1421.	1.1	9
46	Palliative care for drug-resistant tuberculosis: An urgent call to action. <i>South African Medical Journal</i> , 2018, 108, 360.	0.2	0
47	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	6.3	452
48	MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care. <i>PLoS ONE</i> , 2018, 13, e0196003.	1.1	26
49	Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	4
50	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002591.	3.9	96
51	Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic. <i>Clinical Infectious Diseases</i> , 2018, 67, 341-349.	2.9	6
52	Rural medicine and "home stay": a medical student's experience. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2018, 60, 42.	0.2	0
53	CAPRISA 003: Timing of Antiretroviral Initiation in HIV-TB Co-infected Patients – The SAPIT Trial. , 2017, , 107-120.		0
54	Turning the tide against tuberculosis. <i>International Journal of Infectious Diseases</i> , 2017, 56, 6-9.	1.5	4

#	ARTICLE	IF	CITATIONS
55	Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1441-1449.	1.3	38
56	Drug-resistant tuberculosis in patients with minimal symptoms: favourable outcomes in the absence of treatment. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 556-563.	0.6	3
57	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2017, 5, 291-360.	5.2	459
58	Whole genome sequencing for the management of drug-resistant TB in low income high TB burden settings: Challenges and implications. <i>Tuberculosis</i> , 2017, 107, 137-143.	0.8	15
59	A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1369-1386.	1.0	52
60	The World Health Organization excludes <i>Mycobacterium tuberculosis</i> from the 2017 priority pathogens list. <i>South African Medical Journal</i> , 2017, 107, 466.	0.2	1
61	Addressing challenges in scaling up TB and HIV treatment integration in rural primary healthcare clinics in South Africa (SUTHI): a cluster randomized controlled trial protocol. <i>Implementation Science</i> , 2017, 12, 129.	2.5	25
62	Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the <i>UGT1A1*28</i> allele. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume 10, 233-234.	0.4	0
63	High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa. <i>PLoS ONE</i> , 2017, 12, e0184124.	1.1	13
64	Scaling up TB-HIV Integration in Public Health Clinics: Translating Research Findings into Practice. , 2017, , 121-134.		0
65	TB Control in South Africa. , 2017, , 27-33.		0
66	Provider perspectives on drug-resistant tuberculosis and human immunodeficiency virus care in South Africa: a qualitative case study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1483-1488.	0.6	9
67	Elucidating the role of clofazimine for the treatment of tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 52-57.	0.6	21
68	Genomic and functional analyses of <i>Mycobacterium tuberculosis</i> strains implicate <i>ald</i> in D-cycloserine resistance. <i>Nature Genetics</i> , 2016, 48, 544-551.	9.4	145
69	Antibiotic stewardship for drug resistant tuberculosis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1981-1983.	0.9	6
70	Implementation and Operational Research: Clinical Impact of the Xpert MTB/RIF Assay in Patients With Multidrug-Resistant Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, e1-e7.	0.9	14
71	Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 430-434.	0.6	62
72	Primary Capreomycin Resistance Is Common and Associated With Early Mortality in Patients With Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 536-543.	0.9	12

#	ARTICLE	IF	CITATIONS
73	Paediatric chemoprophylaxis for child contacts of patients with drug-resistant tuberculosis: Are current guidelines effective in preventing disease?. <i>South African Medical Journal</i> , 2015, 105, 328.	0.2	0
74	Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates: Table 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 1432-1438.	2.9	38
75	Towards host-directed therapies for tuberculosis. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 511-512.	21.5	110
76	Care of the patient with XDR-TB who has failed treatment. <i>Lancet Respiratory Medicine</i> , 2015, 3, 269-270.	5.2	0
77	Surgical Treatment of Complications of Pulmonary Tuberculosis, including Drug-Resistant Tuberculosis. <i>International Journal of Infectious Diseases</i> , 2015, 32, 61-67.	1.5	34
78	Cellular therapy in Tuberculosis. <i>International Journal of Infectious Diseases</i> , 2015, 32, 32-38.	1.5	26
79	The contrasting cultures of HIV and tuberculosis care. <i>Aids</i> , 2015, 29, 1-4.	1.0	28
80	Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 163-171.	0.6	77
81	Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. <i>PLoS Medicine</i> , 2015, 12, e1001880.	3.9	236
82	Association between Health Systems Performance and Treatment Outcomes in Patients Co-Infected with MDR-TB and HIV in KwaZulu-Natal, South Africa: Implications for TB Programmes. <i>PLoS ONE</i> , 2014, 9, e94016.	1.1	27
83	Understanding the Profile of Tuberculosis and Human Immunodeficiency Virus Coinfection: Insights from Expanded HIV Surveillance at a Tuberculosis Facility in Durban, South Africa. <i>Isrn Aids</i> , 2014, 2014, 1-6.	2.5	5
84	Malnutrition associated with unfavorable outcome and death among South African MDR-TB and HIV co-infected children. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 1074-1083.	0.6	52
85	Preferential adherence to antiretroviral therapy over tuberculosis treatment: A qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. <i>Global Public Health</i> , 2014, 9, 1107-1116.	1.0	61
86	Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3103-3107.	1.3	39
87	Adherence in the Treatment of Patients With Extensively Drug-Resistant Tuberculosis and HIV in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 22-29.	0.9	38
88	Drug-resistant tuberculosis control in South Africa: scientific advances and health system strengthening are complementary. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2113-2116.	0.9	2
89	Changes to Antiretroviral Drug Regimens during Integrated TB+HIV Treatment: Results of the Sapit Trial. <i>Antiviral Therapy</i> , 2014, 19, 161-169.	0.6	16
90	Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 147-154.	0.6	29

#	ARTICLE	IF	CITATIONS
91	Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection. <i>Emerging Infectious Diseases</i> , 2013, 19, 416-424.	2.0	100
92	Systematic review of clofazimine for the treatment of drug-resistant tuberculosis [Review article]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 1001-1007.	0.6	128
93	Health-care workers's perspectives on workplace safety, infection control, and drug-resistant tuberculosis in a high-burden HIV setting. <i>Journal of Public Health Policy</i> , 2013, 34, 388-402.	1.0	37
94	Integrating patients' perspectives into integrated tuberculosis-human immunodeficiency virus health care. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 546-551.	0.6	14
95	Population Pharmacokinetics and Pharmacodynamics of Ofloxacin in South African Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3857-3863.	1.4	32
96	Social constraints to TB/HIV healthcare: Accounts from coinfecting patients in South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 1480-1486.	0.6	54
97	Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 209-215.	0.6	54
98	Lessons from a randomised clinical trial for multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 1582-1587.	0.6	9
99	The Immune Reconstitution Inflammatory Syndrome After Antiretroviral Therapy Initiation in Patients With Tuberculosis: Findings From the SAPIT Trial. <i>Annals of Internal Medicine</i> , 2012, 157, 313.	2.0	101
100	Pulmonary Resection for Extensively Drug Resistant Tuberculosis in Kwazulu-Natal, South Africa. <i>Annals of Thoracic Surgery</i> , 2012, 94, 381-386.	0.7	12
101	A community officer's perspective of a rural hospital in KwaZulu-Natal. <i>South African Medical Journal</i> , 2012, 102, 355.	0.2	1
102	Extensively Drug-Resistant Tuberculosis in Women, KwaZulu-Natal, South Africa. <i>Emerging Infectious Diseases</i> , 2011, 17, 1942-1945.	2.0	16
103	Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis. <i>New England Journal of Medicine</i> , 2011, 365, 1482-1491.	13.9	491
104	Integration of Antiretroviral Therapy with Tuberculosis Treatment. <i>New England Journal of Medicine</i> , 2011, 365, 1492-1501.	13.9	451
105	HIV-Associated Tuberculosis. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-8.	3.3	14
106	Evaluation of Time to Detection of <i>Mycobacterium tuberculosis</i> in Broth Culture as a Determinant for End Points in Treatment Trials. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4370-4376.	1.8	16
107	High Incidence of Hospital Admissions With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Among South African Health Care Workers. <i>Annals of Internal Medicine</i> , 2010, 153, 516.	2.0	151
108	The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. <i>South African Medical Journal</i> , 2010, 100, 808.	0.2	10

#	ARTICLE	IF	CITATIONS
109	Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. <i>New England Journal of Medicine</i> , 2010, 362, 697-706.	13.9	608
110	The whole is greater than the sum of the parts: Recognising missed opportunities for an optimal response to the rapidly maturing TB-HIV co-epidemic in South Africa. <i>BMC Public Health</i> , 2009, 9, 243.	1.2	26
111	Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 273-280.	2.5	247
112	HIV testing and disclosure: a qualitative analysis of TB patients in South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2007, 19, 572-577.	0.6	64
113	XDR-TB in South Africa: No Time for Denial or Complacency. <i>PLoS Medicine</i> , 2007, 4, e50.	3.9	132
114	Managing multiple and extensively drug-resistant tuberculosis and HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1035-1037.	0.9	9
115	Multidrug-Resistant Tuberculous Meningitis in Children in Durban, South Africa. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 147-150.	1.1	60
116	The Early Bactericidal Activities of Rifampin and Rifapentine in Pulmonary Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 128-135.	2.5	102
117	Multidrug-Resistant Tuberculous Meningitis in KwaZulu-Natal, South Africa. <i>Clinical Infectious Diseases</i> , 2004, 38, 851-856.	2.9	78